{
    "id": 3425,
    "fullName": "ERBB2 V777L",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) V777L lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V777L results in increased Erbb2 (Her2) activity, activation of downstream signaling, transformation of cultured cells (PMID: 29967253, PMID: 31588020), increased tumor growth in xenograft models (PMID: 23220880), and confers resistance to selected tyrosine kinase inhibitors (PMID: 31588020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11774,
                    "pubMedId": 29967253,
                    "title": "High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29967253"
                },
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                },
                {
                    "id": 1980,
                    "pubMedId": 23220880,
                    "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23220880"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "V777L",
    "createDate": "03/01/2015",
    "updateDate": "11/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 170798,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39724747G>C",
        "cDna": "c.2329G>C",
        "protein": "p.V777L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2047,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 622,
                "therapyName": "AEE788",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13244,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 6.9 months in a patient with endometrial cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) inhibited survival of transformed cells expressing ERBB2 (HER2) V777L in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7092,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13208,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 6.9 months in a patients with bladder cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13236,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.4 months in a patient with colorectal cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7105,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13250,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.1 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19970,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) inhibited survival of transformed cells expressing ERBB2 (HER2) V777L in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20394,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) V777L in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19145,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ERBB2 (HER2) V777L were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3043,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V777L in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19180,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ERBB2 (HER2) V777L were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2050,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1980,
                    "pubMedId": 23220880,
                    "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23220880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2048,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1980,
                    "pubMedId": 23220880,
                    "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23220880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7088,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20664,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vizimpro (dacomitinib) inhibited survival of transformed cells expressing ERBB2 (HER2) V777L in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7099,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20575,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, the combination of Navelbine (vinorelbine) and Herceptin (trastuzumab) resulted in a partial response with tumor regression in a breast cancer patient harboring ERBB2 (HER2) V777L (PMID: 31118664).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 1890,
                "therapyName": "Trastuzumab + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17940,
                    "pubMedId": 31118664,
                    "title": "A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20528,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pyrotinib inhibited survival of transformed cells expressing ERBB2 (HER2) V777L in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 3082,
                "therapyName": "Pyrotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20423,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Imbruvica (ibrutinib) inhibited survival of transformed cells expressing ERBB2 (HER2) V777L in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20372,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited survival of transformed cells expressing ERBB2 (HER2) V777L in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20541,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarloxotinib (TRLX) inhibited survival of transformed cells expressing ERBB2 (HER2) V777L in culture (PMID: 31588020).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16758,
                    "pubMedId": 31588020,
                    "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31588020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7114,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 4359,
                "therapyName": "Neratinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2049,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1980,
                    "pubMedId": 23220880,
                    "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23220880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13225,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in one patient, and progressive disease in 4 patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13198,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.6 months in one patient, and progressive disease with a progression-free survival of 0.8 months in another patient with biliary tract cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 4607,
                "name": "biliary tract cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7110,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7098,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Erbitux (cetuximab) in culture and in patient-derived xenograft models (PMID: 26243863).",
            "molecularProfile": {
                "id": 3234,
                "profileName": "ERBB2 V777L"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13214,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patients with bladder cancer harboring ERBB2 (HER2) L755S, R1153*, and V777L (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 29029,
                "profileName": "ERBB2 L755S ERBB2 V777L ERBB2 R1153*"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13237,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) V777L and V842I (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 29035,
                "profileName": "ERBB2 V777L ERBB2 V842I"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15747,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L demonstrated resistance when treated with Nolvadex (tamoxifen) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15850,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of VX-11e did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 7755,
                "therapyName": "Fulvestrant + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15840,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 7754,
                "therapyName": "Fulvestrant + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15981,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) V777L in culture (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 5015,
                "therapyName": "Fulvestrant + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15887,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15977,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) V777L in culture resulting in growth inhibition, and the combination of Afinitor (everolimus) and Faslodex (fulvestrant) inhibited tumor growth in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15755,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L demonstrated resistance when treated with GDC-0810 in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15864,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Capivasertib (AZD5363) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15978,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) V777L in culture resulting in growth inhibition, and the combination of Alpelisib (BYL719) and Faslodex (fulvestrant) inhibited tumor growth in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15833,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L were resistant to the combination therapy of Faslodex (fulvestrant) and Ibrance (palbociclib) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15751,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L demonstrated resistance when treated with Faslodex (fulvestrant) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15805,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an estrogen-receptor (ESR1)-positive cell line harboring ERBB2 (HER2) V777L demonstrated resistance to Faslodex (fulvestrant) in culture, and treatment with Faslodex (fulvestrant) resulted in tumor growth arrest, but not regression, in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15766,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Nerlynx (neratinib) results in restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15973,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical study, treatment with the combination of Nerlynx (neratinib) and Faslodex (fulvestrant) inhibited growth and reduced invasive behavior of estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) V777L in culture, to a greater degree than either agent alone, and resulted in tumor regression in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15982,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Nerlynx (neratinib), Afinitor (everolimus), and Faslodex (fulvestrant) induced nearly complete tumor regression in xenograft models of estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) V777L (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 7842,
                "therapyName": "Everolimus + Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16390,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including partial response in a patient harboring ERBB2 (HER2) V777L (PMID: 30301790).",
            "molecularProfile": {
                "id": 31623,
                "profileName": "ERBB2 V777L ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14478,
                    "pubMedId": 30301790,
                    "title": "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30301790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17259,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, NF2 mutations were identified as acquired mutations in ctDNA of a breast cancer patient harboring ERBB2 (HER2) S310F and V777L who developed resistance to Herceptin (trastuzumab) (J Clin Oncol 37, 2019 (suppl; abstr e12518)).",
            "molecularProfile": {
                "id": 32421,
                "profileName": "ERBB2 S310F ERBB2 V777L NF2 mut"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15278,
                    "pubMedId": null,
                    "title": "Acquired NF2 mutations confer resistance to HER2 targeted therapy in HER2-mutant breast cancer.",
                    "url": "http://abstracts.asco.org/239/AbstView_239_249469.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20342,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring ERBB2 (HER2) V777L and PIK3CA H1047R demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35135,
                "profileName": "ERBB2 V777L PIK3CA H1047R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20386,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and Nerlynx (neratinib) worked synergistically to inhibit viability of a breast cancer cell line harboring ERBB2 (HER2) V777L and PIK3CA H1047R in culture (PMID: 31978326).",
            "molecularProfile": {
                "id": 35135,
                "profileName": "ERBB2 V777L PIK3CA H1047R"
            },
            "therapy": {
                "id": 5401,
                "therapyName": "Everolimus + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17814,
                    "pubMedId": 31978326,
                    "title": "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31978326"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3234,
            "profileName": "ERBB2 V777L",
            "profileTreatmentApproaches": [
                {
                    "id": 4495,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB2 V777L"
                },
                {
                    "id": 4496,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB2 V777L"
                }
            ]
        },
        {
            "id": 29029,
            "profileName": "ERBB2 L755S ERBB2 V777L ERBB2 R1153*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29035,
            "profileName": "ERBB2 V777L ERBB2 V842I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31191,
            "profileName": "ERBB2 V777L ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31623,
            "profileName": "ERBB2 V777L ERBB2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32421,
            "profileName": "ERBB2 S310F ERBB2 V777L NF2 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35135,
            "profileName": "ERBB2 V777L PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170798,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39724747G>C",
            "cDna": "c.2329G>C",
            "protein": "p.V777L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170799,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39724747G>C",
            "cDna": "c.2329G>C",
            "protein": "p.V777L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}